|
KMID : 0939920230550010304
|
|
대한암학회지
2023 Volume.55 No. 1 p.304 ~ p.313
|
|
|
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL)
|
|
Kim Kyung-Ha
Lee Jae-Hoon
Kim Hoon-Gu
Do Young-Rok
Park Yong
Oh Sung-Yong
Shin Ho-Jin
Kim Won-Serk
Park Sung-Kyu
Kong Jee-Hyun
Park Moo-Rim
Yang Deok-Hwan
Kwak Jae-Yong
Kang Hye-Jin
Mun Yeung-Chul
Won Jong-Ho
|
|
|
Abstract
|
|
|
Purpose : High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard management for relapsed or high-risk non-Hodgkin’s lymphoma (NHL). We reported the busulfan, melphalan, and etoposide (BuME) conditioning regimen was effective in patients with relapsed or high-risk NHL. Moreover, the busulfan, cyclophosphamide, and etoposide (BuCE) conditioning regimen has been used widely in ASCT for NHL. Therefore, based on these encouraging results, this randomized phase II multicenter trial compared the outcomes of BuME and BuCE as conditioning therapies for ASCT in patients with NHL.
Materials and Methods : Patients were randomly assigned to receive either BuME (n=36) or BuCE (n=39). The BuME regimen was comprised of busulfan (3.2 mg/kg/day, intravenously) administered on days ?7, ?6, and ?5, etoposide (400 mg/m2 intravenously) on days ?5 and ?4, and melphalan (50 mg/m2/day intravenously) on days ?3 and ?2. The BuCE regimen was comprised of busulfan (3.2 mg/kg/day intravenously) on days ?7, ?6, and ?5, etoposide (400 mg/m2/day intravenously) on days ?5 and ?4, and cyclophosphamide (50 mg/kg/day intravenously) on days ?3 and ?2. The primary endpoint was 2-year progression-free survival (PFS).
Results : Seventy-five patients were enrolled. Eleven patients (30.5%) in the BuME group and 13 patients (33.3%) in the BuCE group had disease progression or died. The 2-year PFS rate was 65.4% in the BuME group and 60.6% in the BuCE group (p=0.746). There were no non-relapse mortalities within 100 days after transplantation.
Conclusion : There were no significant differences in PFS between the two groups. Therefore, busulfan-based conditioning regimens, BuME and BuCE, may be important treatment substitutes for the BCNU-containing regimens.
|
|
|
KEYWORD
|
|
|
Autologous stem cell transplantation, Non-Hodgkin’s lymphoma, Busulfan
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|